France - Inventiva (Euronext Paris and Nasdaq: IVA) (the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis ('NASH') and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2022 and its revenues for the first nine months of 2022.

Contact:

Tel: +1 240 620 9175

(C) 2022 Electronic News Publishing, source ENP Newswire